natgillin/translations-raw huggingface dataset:
The method of item 1 wherein more than one immunosuppressive drug is administered. 
Anti-C5 antitijelo za uporabu prema zahtjevu 1, naznačeno time, što treba primijeniti više od jednog dodatnog imunosupresivnog lijeka.
The freeze dried formulation according to claim 6, wherein the follicle-stimulating hormone (FSH) is present at a concentration of at or about 0.3 to 5 µg/mg of the total formulation. 
Smrzavanjem osušena formulacija prema zahtjevu 6, naznačena time da je folikulostimulirajući hormon (FSH) prisutan u koncentraciji od ili oko 0.3 do 5 ug/mg ukupne formulacije.
For dental applications, a suitable medium would be the tooth in which the dental filling material is placed or a metal matrix typically used for making cavities in molar teeth. 
Za dentalnu primjenu pogodni medij ćc biti zub u kojem je dentalno punilo smješteno ili metalna matrica koje se tipično koristi za izradu šupljina u kutnjaku.
The method according to any of the preceding claims, wherein the raw paper (2) is impregnated from above and from below. 
Metoda u skladu sa patentnim zahtjevima 2 ili 3, gdje je papir (2) tanak sirov papir sa težinom od oko 40 - 60 g/m2.
A composition according to claim 1 or 2, wherein said disaccharide is selected from the group consisting of lactose, trehalose, sucrose, and mixtures thereof. 
Smjesa prema patentnom zahtjevu I ili 2, naznačena time što je navedeni disaharid izabran iz grupe koju čine laktoza, trehaloza, saharoza i njihove smjese.
The cracking furnace according to claim 11, wherein at least a subset of coils of the plurality of cracking coils is arranged in a arrangement configured for parallel flow of the feed through each coil of the subset of coils during use. 
Peć za cijepanje prema bilo kojem zahtjevu 7 do 13, naznačena time, da su barem neke od spirala za cijepanje raspoređene u poretku koji dozvoljava paralelni protok opskrbnog materijala kroz svaku spiralu, prilikom uporabe. .
Preferably, the base unit 3 further comprises a seal (not shown) fixed to the lower edge of the outer wall 16. 
Ponajprije, osnovni dio 3 obuhvaća, nadalje, brtvu (koja nije prikazana) učvršćenu za donji rub vanjske stijenke 16.
A ddRNAi agent according to claim 6, wherein at least one of the other effector sequences is SEQ ID NO: 9. 
Agens za ddRNKi prema patentnom zahtjevu 7, gdje najmanje jedna od drugih efektorskih sekvenci je sekvenca izabrana od sekvenci navedenih u SEQ ID NO: 3, 12, 13123.
providing particulate expandable polylactic acid according to any one or more of claims 1-11 or produced by a method according to either one or both of claims 12-13; ii) bringing the particulate expandable polylactic acid in step i) under specific temperature and pressure conditions so that a foamed moulded product is obtained. 
osiguravanja partikulirane proširljive polimliječne kiseline u skladu s bilo kojim od ili više patentnih zahtjeva 1-11 ili proizvedene postupkom u skladu s bilo kojim od ili oba od patentnih zahtjeva 12-13; ii) stavljanja partikulirane proširljive polimliječne kiseline iz koraka i) u specifične uvjete temperature i tlaka, tako da se dobije pjenasti oblikovani proizvod.
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:119 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:118; 
(DD VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 119i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 118;
Suitable divalent linkers include, by way of example, those derived from dicarboxylic acids, disulfonylhalides; dialdehydes, diketones, dihalides, diisocyanates, diamines, diols, mixtures of carboxylic acids, sulfonylhalides, aldehydes, ketones, halides, isocyanates, amines and diols. 
Odgovarajući divalentni veznici uključuju, na primjer, one dobivene iz dikarboksilnih kiselina, disulfonilhalida, dialdehida, diketona, dihalida, diizocijanata, diamina, diola, smjesa karboksilnih kiselina, sulfonilhalida, aldehida, ketona, halida, izocijanata, amina i diola.
In an even more preferred embodiment of the pharmaceutical methods of the invention, the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 15µg, 30µg, 60 µg or 90 µg per square meter patient body surface area. 
Konstrukt za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što se CD19xCD3 konstrukt protutijela bispecifičnog jednostrukog lanca daje u dnevnoj dozi od 15 ug do 30 ug po kvadratnom metru površine tijela pacijenta.
Some such mutant CTLA-4 ECD polypeptides in such a fusion protein comprise a polypeptide sequence which differs from the selected polypeptide sequence by no more than 6 amino acid residues and which includes amino acid residues at positions 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 and 106 that are identical to the amino acid residues at the corresponding positions in the selected polypeptide sequence. Such mutant CTLA-4 ECD polypeptide can differ from the selected polypeptide sequence by amino acid deletion(s), addition(s), and/or amino acid substitution(s). 
Izolirani ili rekombinantni polipeptid koji sadrži polipeptidnu sekvencu koja se razlikuje od SEQ ID NO:36 u ne više od 6 aminokiselinskih ostataka 1 koja uključuje ostatke na položajima 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 1 106 koji su identični sa aminokiselinskim ostatcima na odgovarajućim položajima u SEQ ID NO:36, naznačen time da polipeptid veže humani CD80 ili humani CD86 ili izvanstaničnu domenu bilo kojeg od njih i ima sposobnost inhibicije imunološkog odgovora koja je veća od sposobnosti inhibicije imunološkog odgovora polipeptida LEA29Y koji sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:168.
That is, the starting location of the common search space is fixed to all UEs in the cell. 
HR P20120507 T1 pri čemu je početna lokacija ZU za UE specifični prostor pretraživanja definirana sa:
The pharmaceutical composition according to any one of the preceding claims, wherein the mRNA encodes two or more distinct proteins. 
Nosač transfera prema bilo kom od zahtjeva 2 do 6, naznačen time što je nosač transfera lipidna nanočestica ili liposom.
wherein * indicates the point of attachment of said group with the rest of the molecule; and 
pri čemu * označava točku vezanja navedene skupine s ostatkom molekule; i
The invention also provides for the use of eltrombopag olamine in the manufacture of a solid oral pharmaceutical dosage form of the present invention for use in treating thrombocytopenia. 
6. Uporaba farmaceutske tablete prema zahtjevima 1-2 u proizvodnji lijeka za agonističko djelovanje na TPO receptor.
The method according to claim 21, wherein said body of permanent-magnetic material is a polymer-bonded composite which comprises a macromolecular polymer and a permanent-magnetic powder, wherein the permanent-magnetic powder is selected from the group of magnetic materials consisting of cobalt, iron, and their alloys, chromium dioxide, magnetic oxide spinels, magnetic garnets, magnetic ferrites including magnetic hexaferrites, alnico alloys, samarium-cobalt alloys, and rare-earth-iron-boron alloys. 
Postupak sukladno jednom od patentnih zahtjeva 7 do 9, naznačen time, da je navedeno tijelo od permanentno magnetskog materijala izrađeno od kompozitnog materijala vezanog polimerom koje uključuje makromolekularni polimer i prašak permanentno magnetskog materijala, pri čemu je magnetski prašak odabran iz skupine koju čine magnetski materijali u koje spadaju kobalt, željezo i njihove legure, krom dioksid, magnetski oksid spineli, magnetski granati, magnetski feriti uključujući magnetske heksaferite, alnico legure, legure samarij-kobalta i legure rijetka zemlja-željezo-bor.
The immunobinder of claim 28, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 164 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 87. An antigen-binding fragment of the immunobinder of claim 28 or 29, wherein the fragment is an scFv or a Fab, a F(ab')2 or a Fab'. 
Uporaba protutijela ili njegovog ulomka koji veže antigen, naznačena time, da služi u proizvodnji lijeka za liječenje bolesti posredovane s VEGF, pri čemu protutijelo ili njegov ulomak koji veže antigen obuhvaća varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 164 i varijabilni laki lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 87.
it has an increased activity and/or increased yield in particular compared to at least one protein molecule composition of the same protein molecule when expressed in the cell line ATCC No. 
- ima povišenu aktivnost i/ili povećani prinos, osobito u usporedbi s pripravkom s najmanje jednom molekulom proteina za istu molekulu proteina kada se eksprimira u staničnoj liniji ATCC No.
All the process steps of a corresponding production process which are disclosed there, and all the material specifications which are disclosed there, as well as the tools which are used, etc., can also be used within the scope of the process according to the present invention. 
US 5,547,094 također opisuje korake odgovarajućeg proizvodnog postupka i sve opise materijala koji su ovdje opisani, kao također i alate koji se upotrebljavaju u predloženom izumu.
A compound selected from the group: (1; 2) 
Spoj naznačen time što je odabran iz skupine koji čine:
a protected isoleucine, particularly Fmoc-protected isoleucine (Fmoclle); 
(vi) zaštićeni izoleucin, osobito zaštićeni Fmoc-izoleucin (EmocGly);
wherein when R1 is C1-2alkyl, said C1-2alkyl is optionally substituted with one to two substituents independently selected from the group consisting of C1-6alkoxy, aryl, cycloalkyl, heterocyclyl, hydroxy, cyano, amino, C1-6alkylamino, (C1-6alkyl)2amino, trifluoromethyl, and carboxy; 
Spoj prema zahtjevu 1 naznačen time da R? je jedan do dva supstituenta nezavisno izabrana iz skupine koju čine C,.salkil, halogen, i aril; pri čemu aril je proizvoljno supstituiran s jednim do tri supstituenta nezavisno izabrana iz skupine koju čine halogen, karboksi, aminokarbonil, Cisalkilsulfonilamino, cijano, hidroksi, amino, C;.salkilamino, 1 (Cr3alkil)pamino.
A process for preparing a compound of formula I as defined in claim 1, which process comprises 
Proces za pripremu spoja formule I kao što je definirano u zahtjevu 1, gdje proces obuhvaća a) reakciju spoja formule
A therapeutic nanoparticle for use as a medicament, as claimed in any one of claims 1 to 13, wherein the nanoparticle includes about 1 to about 20 weight percent of the therapeutic agent, e.g. about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19 or about 20 weight percent of the therapeutic agent. 
: HR P20191187T1 Terapijska nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačena time što nanočestice sadrže otprilike 1 do otprilike 20 težinskih postotaka terapijskog sredstva, primjerice otprilike 1, otprilike 2, otprilike 3, otprilike 4, otprilike 5, otprilike 6, otprilike 7, otprilike 8, otprilike 9, otprilike 10, otprilike 11, otprilike 12, otprilike 13, otprilike 14, otprilike 15, otprilike 16, otprilike 17, otprilike 18, otprilike 19 ili otprilike 20 težinskih postotaka terapijskog sredstva.
Method according to claim 4 or 5 characterized by the fact that said steps of selecting and storing are executed through a "drag&drop" of the multimedia content (R1,..., RN) from said area (A1,..., An) to the storage folder (C). 
Metoda prema patentnom zahtjevu 4 ili 5, naznačena time da su navedeni koraci odabira i spremanja izvršeni povlačenjem 1 ispuštanjem" multimedijalnog sadržaja (RI,..., RN) s navedenog odjeljka (Al,..., An) u mapu za pohranu (C).
A pharmaceutical preparation comprising a solution of methylnaltrexone or a salt thereof and a chelating agent, wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA) or a derivative thereof, niacinamide or a derivative thereof, or sodium desoxycholate or a derivative thereof. 
HR P20150037 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak koji sadrži otopinu metilnaltreksona ili njegove soli i kelatirajući agens, naznačen time da je kelatirajući agens etilendiamintetraoctena kiselina (EDTA) ili njen derivat, niacinamid ili njegov derivat ili natrij dezoksikolat ili njegov derivat.
Accordingly the new use of said compounds forms part of the present invention. 
S tim u skladu, nova upotreba spomenutih spojeva tvori dio predloženog izuma.
Pharmaceutical compositions for the treatment of inflammatory disorders 
FARMACEUTSKE KOMPOZICIJE ZA LIJEČENJE INFLAMATORNIH POREMEĆAJA
The method of claim 1, wherein the E. coli is a Shiga toxin-producing E. coli (STEC), an Enterotoxigenic E. coli (ETEC) or an Enteropathogenic E. coli (EPEC). 
Oralno farmaceutski spoj za za uporabu sukladno bilo kojem od prethodnih zahtjeva, naznačena time što je E. coli Shiga toksin-koji proizvodi E. coli (STEC), Enterotoksigene E. coli (ETEC) ili Enteropatogene E. coli (EPEC).
The cell culture system of claim 5, wherein the procoagulant blood Factor protein is Factor IX, which is human Factor IX. 
Sustav stanične kulture prema zahtjevu 12, naznačen time, da faktor zgrušavanja krvi je humani faktor IX.
A further consequence of the up-side down orientation of the container is that the pressure required for emptying the collapsible container is reduced, thus allowing a choice of lighter materials for the component parts of the dispensing assembly. 
Daljnja posljedica usmjerenosti spremnika gore-dolje je manji pritisak potreban za pražnjenje sklopivog spremnika, čime je omogućen izbor lakših materijala za dijelove komponenata sklopa za točenje.
The human T cell of claim 9, wherein the 4-1BB costimulatory signaling region is encoded by a nucleic acid sequence comprising SEQ ID NO: 17. The human T cell of claim 10, wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 18. 
(ili) anti-CD19 scFv je kodirano sekvencom SEQ ID NO: 14; HR P20182202 T1 (iv) signalno područje 4-IBB je kodirano sekvencom SEQ ID NO: 17 i signalno područje CD3 zeta je kodirano sekvencom SEQ ID NO:18;
the other disease or condition is selected from the group consisting of: pulmonary hypertension, blood vessel-related disease such as arterial stiffness or mediasclerosis or arteriosclerosis, gut sclerosis, systemic sclerosis, retroperitoneal fibrosis, proliferative fibrosis, neoplastic fibrosis, nephrogenic systemic fibrosis, injection fibrosis, mediastinal fibrosis, myelofibrosis, post-vasectomy pain syndrome, and rheumatoid arthritis. 
Spoj prema zahtjevu 1 za uporabu prema zahtjevu 1, naznačen time da subjekt ima najmanje jednu drugu bolest ili stanje odabrano iz skupine koja sadrži plućnu hipertenziju, bolest povezanu sa krvožilnih sustavom, crijevnu sklerozu, retroperitonealnu fibrozu, proliferativnu fibrozu, neoplastičnu fibrozu, nefrogenu sistemsku fibrozu, injekcijsku fibrozu, medijastinalnu fibrozu, mijelofibrozu, sindrom boli nakon vazektomije, reumatoidni artritis.
The pallet container of claim 3, wherein two of the four separate blank panels are dissimilar in size and provided for two shorter ones of the side walls, said overlapping strips of the two blank panels having different widths to define for the upper base a cover flap comprised of the first cover flap and a third cover flap, with the overlapping strip of one of the two dissimilar blank panels, provided for a rearward one of the shorter side walls, being defined by a width of approx. 300 mm to 550 mm and with the overlapping strip of the other one of the two dissimilar blank panels, provided for a front-side one of the shorter side walls, being defined by a width of approx. 1100 mm to 600 mm. 
Paletni spremnik prema patentnom zahtjevu 2, naznačen time što unutarnji spremnik od plastičnog materijala ima dvije kraće bočne stjenke, pri čemu dvije prazne ploče različitih veličina protupožarne izolacijske prostirke (20) za dvije kraće bočne stjenke unutarnjeg spremnika od plastičnog materijala imaju dvije različite široke preklopne trake kao zaklopce pokrova za gornju osnovicu, pri čemu stražnja prazna ploča protupožarne izolacijske prostirke (20) ima preklopnu traku koja ima širinu od približno 300 mm do 550 mm, poželjno od približno 450 mm, a prednja prazna ploča protupožarne izolacijske prostirke (20) ima preklopnu traku koja ima širinu od približno 1100 mm do 600 mm, poželjno približno 850 mm.
contacting a compound of formula (VI): wherein R3 and R4 are as previously described; with acetic acid and water under conditions suitable for forming the compound of formula (V): 
an OR? pri čemu R> i R* su svaki neovisno Ci. alkil; s octenom kiselinom i vodom pod uvjetima koji su pogodni za nastajanje spoja s formulom (V): or | 07
Female CD-1 mice 5-8 weeks of age are dosed with a compound of formula I by oral gavage. A dose level is chosen to approximate a molar equivalent of 8-mg/kg gemcitabine. 
Ženkama CD-1 miševa starim 5-8 tjedana oralno je doziran spoj formule I. Razina doze odabrana je tako da bude približno molarno ekvivalentna 8 mg/kg gemcitabina.
The extended release dosage form of any one of claims 1 to 12, wherein the dosage form comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, 80 mg, 90 mg, 120 mg or 160 mg of oxycodone hydrochloride. 
Oblik davanja s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 12, naznačen time da oblik davanja sadrži 5 mg, 7,5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, 80 mg, 90 mg, 120 mg ili 160 mg oksikodon hidroklorida.
A pharmaceutical composition according to claim 5 comprising a crystalline form of a compound of Formula XI 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1, 5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide substantially in the form of Form 1 characterized by an X-ray diffraction pattern having characterizing peaks at about 9.2 and 13.0 on the 2θ scale, in combination with an anti-tumor agent or a signal transduction inhibitor. 
Kristalni oblik spoja formule XI [image] bitno u obliku oblika 1, 2-(2-fluoro-4-jodofenilamino)-N-(2-hidroksietoksi)-1,5-dimetil-6-okso-1,6-dihidropiridin-3-karboksamid naznačen time da uzorkom rendgenske difrakcije koja ima karakterizirajuće šiljke na oko 9.2 i 13.0 na skali 2θ.
Such excipients are well known and do not need to be discussed in detail here. 
Takve pomoćne tvari su dobro poznate i ovdje ih nije potrebno detaljnije komentirati.
According to a first aspect thereof, the present invention relates to a packaging material for a pharmaceutical product having a coloured element which at about 38° C. discolours partially, revealing a marking, wherein: 
Pakirni materijal (1, 11) za farmaceutski proizvod, naznačen time, da ima obojani element (2, 12) koji djelomično gubi boju na temperaturi od oko 38"C, otkrivajući time oznaku (2, 12'), pri čemu:
Fig. 14 schematically shows a perspective view of a planing device which preferably is used in the scope of the present invention; 
Slika 14 shematski prikazuje pogled u perspektivi na uređaj za ravnanje, za koji je poželjno da se koristi u djelokrugu predmetnog izuma;
Samples A were wrapped in aluminium foil and placed in a sunbox together with the other samples and illuminated for 30 minutes with the Xenon lamp used in Example 3. 
Uzorci A su umotani u aluminijsku foliju i stavljeni u sunčanu kutiju zajedno s ostalim uzorcima i osvijetljeni na 30 minuta pomoću Xenon lampe upotrijebljene u primjeru 3.
Often one uses expandable bolts, so called swelling bolts where the bolt comprises a tube, the interior of which is pressurized by means of a pressure means, such as a high pressure fluid, and thereby expands. 
Često se koriste ekspanzivna sidra, takozvana "swelling bolts" kod kojih sidro sadrži cijev, od koje se unutrašnjost tlači pomoću sredstva za tlačenje, kao što je fluid visokog pritiska, te na taj način ekspandira.
determining a periodicity of the semi-persistent scheduling mode. The method of claim 6, wherein changing the scheduling mode comprises deactivating the semi-persistent scheduling mode, wherein deactivating semi-persistent scheduling mode includes de-allocating the fixed set of recurring resource blocks when a packet size is larger or smaller than the fixed set of recurring resource blocks and a periodicity of the allocation changes. 
Postupak prema Zahtjevu 6, naznačen time što promjena načina planiranja obuhvaća deaktiviranje semi-perzistentnog načina planiranja, gdje deaktiviranje semi-perzistentnog načina planiranja obuhvaća dealokaciju fiksnog skupa ponavljajućih resursnih blokova kada je veličina paketa veća ili manja od fiksnog skupa ponavljajućih resursnih blokova i kada se periodičnost raspodjele mijenja.
is C1-C3 alkyl or cyclopropyl, wherein alkyl or cyclopropyl is optionally substituted with one to three fluoro atoms; is hydrogen; 
je C1-C3 alkil ili ciklopropil, u kome je alkil ili ciklopropil po izboru supstituiran sa jednim do tri atoma fluora;
The disarming system for disarming the components of an ammunition cartridge (10) according to any of claims 6 to 8, characterized in that at least one of its elements is interchangeable for adapting its operation to different gauges of ammunition cartridges (10). 
Sustav za razoružavanje, namijenjen razoružavanju komponenti čahure streljiva (10) u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačen time što je najmanje jedan od njegovih elemenata međusobno zamjenjiv, radi prilagođavanja njegovog rada različitim kalibrima čahura streljiva (10).
The method of claim 7, wherein the non-polar organic solvent is a straight-chain or branch-chain (C4-C10)aliphatic hydrocarbon, a (C4-C10)cycloaliphatic hydrocarbon, or any mixture thereof, wherein the straight-chain or branch-chain hydrocarbon is preferably pentane, hexane, heptane, isooctane, or any mixture thereof and is more preferably n-heptane. 
Postupak prema zahtjevu 7, naznačen time da ne-polarno organsko otapalo je ravnolančani ili razgranati (C4C10)alifatski ugljikovodik, (C4-C10)cikloalifatski ugljikovodik, ili bilo koja njihova smjesa, pri čemu je ravnolančani ili razgranati ugljikovodik poželjno pentan, heksan, heptan, izooktan, ili bilo koja njihova smjesa i poželjnije je n-heptan.
a compound of formula I is prepared wherein R3 and R4 are both hydrogen, herein represented by formula I-a, by an uracil to cytosine conversion reaction from a 2'-deoxy-2'-spirocyclopropyl uridine 1f to the corresponding 2'-deoxy-2'-spirocyclopropyl cytidine 1g, followed by removal of the protecting groups PG yielding compound I-a: 
(a) priprema spoj sa formulom I pri čemu R* i R* su oba vodik, ovdje prikazano sa formulom I-a, pomoću reakcije konverzije uracila u citozm od 2'-deoksi-2'-spirociklopropil uridina 1f u odgovarajući 2'-deoksi-2'- spirociklopropil citidin 1g, nakon čega slijedi uklanj m. zaštitnih skupina PG da se dobije spoj I-a: konverzija
Y is Y-1 or Y-4. The method of claim 8, wherein in the compound of formula (I): 
Veterinarski ili agrikulturni sastav prema zahtjevu 10 ili zahtjevu 11, naznačen time, da u spoju dihidroazola formule (I):